ROIVANT SCIENCES LTD. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ROIVANT SCIENCES LTD. (ROIV) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $196.00 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-20.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-05-20
- ROIVANT SCIENCES LTD. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2026 was $196.00M, a 37.64% increase from fiscal 2025.
- ROIVANT SCIENCES LTD. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $142.40M, a 54.28% increase from fiscal 2024.
- ROIVANT SCIENCES LTD. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $92.30M, a 42.95% decline from fiscal 2023.
- ROIVANT SCIENCES LTD. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $161.80M, a 22.73% decline from fiscal 2022.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2026-03-31 | $196.00M 10-K · filed 2026-05-20 |
| 2025-03-31 | $142.40M 10-K · filed 2025-05-29 |
| 2024-03-31 | $92.30M 10-K · filed 2024-05-30 |
| 2023-03-31 | $161.80M 10-K · filed 2023-06-28 |
| 2022-03-31 | $209.40M 10-K · filed 2022-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |